Navigation Links
NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
Date:7/11/2008

SAN MATEO, Calif., July 11 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the initiation of its Phase 1 clinical trial (study C203) of NGX-1998. The product candidate is a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.

The randomized, single-blind Phase 1 trial is designed to evaluate potential control formulations for future NGX-1998 clinical trials. NeurogesX expects to complete the trial by the end of 2008.

Anthony DiTonno, President and CEO of NeurogesX, commented, "The initiation of this Phase 1 trial of NGX-1998 marks a significant step in our program to develop a second-generation liquid formulation of capsaicin to manage pain. We believe that our Phase 1 trial will provide us with important information that will help shape the design of further studies with the product candidate. We are pleased with the Company's progress with NGX-1998 advancing in the clinic and NGX-4010 under regulatory review in Europe and approaching NDA submission in the United States."

About NGX-1998

NGX-1998 is a topically applied, high-concentration liquid formulation of capsaicin designed to treat pain associated with neuropathic pain conditions. The objective of the NGX-1998 development program is to determine the ability of NGX-1998 to provide protracted pain relief from a single treatment. Similar to NGX-4010, the Company's late-stage dermal patch that also contains a high concentration of capsaicin, NGX-1998 is designed to deliver localized pain relief however, with a shorter treatment procedure time and potentially wit
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Roughly three-quarters ... very confident substituting an interchangeable biosimilar for its ... the same nonproprietary name, according to a survey ... (AMCP,s) Journal of Managed Care & Specialty ... 25 percent of pharmacists would feel as confident ...
(Date:2/27/2015)... Feb. 27, 2015  Pomerantz LLP is investigating claims ... or the "Company") (NASDAQ: VTAE ).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On February 27, 2015, the Company ...
(Date:2/27/2015)... February 27, 2015 ... dell,innovativo sistema di monitoraggio dell,infarto congestizio (CHF - ...     Vectorious ... nuovo sistema per il monitoraggio cardiaco destinato a ... oggi di aver concluso una raccolta di finanziamenti ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... FREMONT, Calif., Nov. 19 Quark Pharmaceuticals, Inc., the leader ... its siRNA R&D platform based programs have met clinical development ... a new IND opened for ocular neuroprotection drug candidate QPI ... has completed enrollment in a Phase 2 study of PF-4523655 ...
... Nov. 19 Radiall and Integral Process will collaborate in ... agreement to confirm this new alliance. , Radiall has a ... time, the company has established relationships with major players in ... , Integral Process is a key supplier of interconnect ...
Cached Medicine Technology:Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 2Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 3Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 4Radiall and Integral Process Sign Agreement 2
(Date:2/28/2015)... In a recent episode of SCI ... Change Athlete Development Services and Consultancy talks with ... athlete development and player engagement during and after their ... athletes face and how off-field activities are a critical ... involved in athlete development issues while in graduate school ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax accounting ... consulting services in addition to a variety of other ... planning. Company finances are a complicated matter that should ... this, complex Canadian tax laws can make it even ... Mew and Company works to advise their clients on ...
(Date:2/28/2015)... 2015 A study out of the ... therapy procedure for the treatment of a hereditary ocular ... Authored by Dr. Robert MacLaren, professor of ophthalmology ... Lancet Medical Journal on January 16, 2014 , the ... genetic disorder that mostly affects men and leads to ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be ... Materials Show, an annual, premier sustainable building event in ... top manufacturers of the latest building products, services and ... and manufactured by Pioneer Millworks from their Oregon and ... restaurants, hotels, retailers, and corporate offices. Nichibi Global ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... -- One of the best ways to encourage ... is to use a personalized approach, according to ... new study shows that simple, personalized interventions that ... improve colorectal cancer screening rates in primary care ...
... starting experiencing sounds as bodily sensations , , MONDAY, Sept. ... experienced sounds as bodily sensations after suffering a small ... the brain processes sensory signals and fixes itself when ... sound after suffering a stroke that only affected part ...
... Longs Drugs,(NYSE: LDG ) announced its flu immunization ... help residents of those communities remain,healthy and combat the annual ... to better meet its customers, needs. -- Longs Drugs ... beginning in October through the middle of ...
... MOUNT VERNON, Wash., Sept. 24 PreViser ... risk and disease analysis,software that enhances treatment ... a simultaneous release of a new corporate ... *(LOGO: http://www.Send2Press.com/mediaboom/07-0924-Previser_72dpi.jpg ) PreViser,s ...
... procedures, both surgical,and nonsurgical, have risen in popularity ... shows such as "Extreme Makeover." And, of course, ... "Nip/Tuck." Nearly 11.5 million cosmetic procedures were ... the American Society for Aesthetic Plastic,Surgery (ASAPS). ...
... websites with its newest category ... ... Great Consumer Driven Health Plan Websites, ... Conference in Philadelphia, the recognition,of the Nation,s Top 20 ... of data using the Healthcare Market Guide, and a,syndicated ...
Cached Medicine News:Health News:Jefferson researchers find personalized interventions key to improving colon cancer screening rates 2Health News:Study Offers Insights Into Sensory Perceptions 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 3Health News:PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software 2Health News:Study Shows Cosmetic Surgery on the Rise as Safety and Efficacy of Procedures Increase 2Health News:Top Twenty Health Plan Websites Named by TheRatingsGuy.com 2Health News:Top Twenty Health Plan Websites Named by TheRatingsGuy.com 3
... with the MAMMOTOME® HH (Hand ... invasive procedure using ultrasound imaging ... images to locate breast abnormalities, ... and map the area you ...
... A biopsy with the MAMMOTOME® ... effective, minimally invasive procedure using ... management.,Using computer-generated images to locate ... accurately pinpoint and map the ...
... occlusive wrap than VICRYL knitted mesh. Especially ... be contained. Predictable absorption. Polyglactin 910 has ... nonpyrogenic. ,VICRYL (polyglactin 910) woven mesh is ... glycolide and lactide, derived respectively from glycolic ...
... Line Reinforcement Material is a safe, ... air leaks and as such, the ... biocompatible, ePTFE material requires no pretreatment ... load and fire and the material's ...
Medicine Products: